Vanda Pharmaceuticals Inc.
VNDA
$4.42
$0.1052.44%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 203.47M | 201.35M | 198.77M | 190.86M | 182.02M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 203.47M | 201.35M | 198.77M | 190.86M | 182.02M |
| Cost of Revenue | 11.40M | 11.40M | 11.31M | 12.18M | 12.70M |
| Gross Profit | 192.07M | 189.96M | 187.46M | 178.67M | 169.33M |
| SG&A Expenses | 191.56M | 166.41M | 146.41M | 130.75M | 117.94M |
| Depreciation & Amortization | 7.01M | 7.01M | 7.27M | 6.47M | 5.10M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 304.28M | 273.80M | 239.43M | 228.33M | 214.49M |
| Operating Income | -100.81M | -72.45M | -40.66M | -37.48M | -32.47M |
| Income Before Tax | -85.00M | -55.63M | -22.92M | -18.09M | -11.96M |
| Income Tax Expenses | -18.06M | -11.38M | -4.02M | -1.70M | -1.03M |
| Earnings from Continuing Operations | -66.94 | -44.25 | -18.90 | -16.39 | -10.93 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -66.94M | -44.25M | -18.90M | -16.39M | -10.93M |
| EBIT | -100.81M | -72.45M | -40.66M | -37.48M | -32.47M |
| EBITDA | -92.87M | -64.56M | -32.53M | -30.16M | -26.54M |
| EPS Basic | -1.14 | -0.76 | -0.33 | -0.28 | -0.19 |
| Normalized Basic EPS | -0.98 | -0.67 | -0.32 | -0.29 | -0.22 |
| EPS Diluted | -1.15 | -0.77 | -0.33 | -0.29 | -0.20 |
| Normalized Diluted EPS | -0.98 | -0.67 | -0.32 | -0.29 | -0.22 |
| Average Basic Shares Outstanding | 234.09M | 233.32M | 232.55M | 231.78M | 231.03M |
| Average Diluted Shares Outstanding | 234.09M | 233.32M | 232.55M | 231.78M | 231.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |